• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 4:00:58 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FENC alert in real time by email
    SC 13G/A 1 d111041dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Fennec Pharmaceuticals Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    31447P100

    (CUSIP Number)

    December 31, 2020

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


      1    

      Names of Reporting Persons.

      I.R.S. Identification Nos. of above persons (entities only)

     

      Southpoint Master Fund, LP

      2  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization.

     

      Cayman Islands

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0 shares

       6   

      Shared Voting Power

     

      4,077,214 shares

     

      Refer to Item 4 below.

       7   

      Sole Dispositive Power

     

      0 shares

       8   

      Shared Dispositive Power

     

      4,077,214 shares

     

      Refer to Item 4 below.

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      4,077,214 shares

     

      Refer to Item 4 below.

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐ N/A

    11  

      Percent of Class Represented by Amount in Row (9)*

     

      15.8%

     

      Refer to Item 4 below.

    12  

      Type of Reporting Person (See Instructions)

     

      PN (Limited Partnership)


      1    

      Names of Reporting Persons.

      I.R.S. Identification Nos. of above persons (entities only)

     

      Southpoint Capital Advisors LP

      2  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization.

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0 shares

       6   

      Shared Voting Power

     

      4,077,214 shares

     

      Refer to Item 4 below.

       7   

      Sole Dispositive Power

     

      0 shares

       8   

      Shared Dispositive Power

     

      4,077,214 shares

     

      Refer to Item 4 below.

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      4,077,214 shares

     

      Refer to Item 4 below.

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐ N/A

    11  

      Percent of Class Represented by Amount in Row (9)*

     

      15.8%

     

      Refer to Item 4 below.

    12  

      Type of Reporting Person (See Instructions)

     

      PN (Limited Partnership)


      1    

      Names of Reporting Persons.

      I.R.S. Identification Nos. of above persons (entities only)

     

      Southpoint Capital Advisors LLC

      2  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization.

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0 shares

       6   

      Shared Voting Power

     

      4,077,214 shares

     

      Refer to Item 4 below.

       7   

      Sole Dispositive Power

     

      0 shares

       8   

      Shared Dispositive Power

     

      4,077,214 shares

     

      Refer to Item 4 below.

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      4,077,214 shares

     

      Refer to Item 4 below.

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐ N/A

    11  

      Percent of Class Represented by Amount in Row (9)*

     

      15.8%

     

      Refer to Item 4 below.

    12  

      Type of Reporting Person (See Instructions)

     

      OO (Limited Liability Company)


      1    

      Names of Reporting Persons.

      I.R.S. Identification Nos. of above persons (entities only)

     

      Southpoint GP, LP

      2  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization.

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0 shares

       6   

      Shared Voting Power

     

      4,077,214 shares

     

      Refer to Item 4 below.

       7   

      Sole Dispositive Power

     

      0 shares

       8   

      Shared Dispositive Power

     

      4,077,214 shares

     

      Refer to Item 4 below.

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      4,077,214 shares

     

      Refer to Item 4 below.

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐ N/A

    11  

      Percent of Class Represented by Amount in Row (9)*

     

      15.8%

     

      Refer to Item 4 below.

    12  

      Type of Reporting Person (See Instructions)

     

      PN (Limited Partnership)


      1    

      Names of Reporting Persons.

      I.R.S. Identification Nos. of above persons (entities only)

     

      Southpoint GP, LLC

      2  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization.

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0 shares

       6   

      Shared Voting Power

     

      4,077,214 shares

     

      Refer to Item 4 below.

       7   

      Sole Dispositive Power

     

      0 shares

       8   

      Shared Dispositive Power

     

      4,077,214 shares

     

      Refer to Item 4 below.

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      4,077,214 shares

     

      Refer to Item 4 below.

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐ N/A

    11  

      Percent of Class Represented by Amount in Row (9)*

     

      15.8%

     

      Refer to Item 4 below.

    12  

      Type of Reporting Person (See Instructions)

     

      OO (Limited Liability Company)


      1    

      Names of Reporting Persons.

      I.R.S. Identification Nos. of above persons (entities only)

     

      John S. Clark II

      2  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization.

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0 shares

       6   

      Shared Voting Power

     

      4,077,214 shares

     

      Refer to Item 4 below.

       7   

      Sole Dispositive Power

     

      0 shares

       8   

      Shared Dispositive Power

     

      4,077,214 shares

     

      Refer to Item 4 below.

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      4,077,214 shares

     

      Refer to Item 4 below.

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐ N/A

    11  

      Percent of Class Represented by Amount in Row (9)*

     

      15.8%

     

      Refer to Item 4 below.

    12  

      Type of Reporting Person (See Instructions)

     

      IN


    Item 1.

     

      (a)

    Name of Issuer

    Fennec Pharmaceuticals Inc.

     

      (b)

    Address of Issuer’s Principal Executive Offices

    PO Box 13628

    68 TW Alexander Drive

    Research Triangle Park, North Carolina 27709

    Item 2.

     

      (a)

    Name of Person Filing

    Southpoint Master Fund, LP

    Southpoint Capital Advisors LP

    Southpoint Capital Advisors LLC

    Southpoint GP, LP

    Southpoint GP, LLC

    John S. Clark II

     

      (b)

    Address of Principal Business Office or, if none, Residence

    1114 Avenue of the Americas, 22nd Floor

    New York, NY 10036

     

      (c)

    Citizenship

    Southpoint Master Fund, LP - Cayman Islands

    Southpoint Capital Advisors LP - Delaware

    Southpoint Capital Advisors LLC - Delaware

    Southpoint GP, LP - Delaware

    Southpoint GP, LLC - Delaware

    John S. Clark II - United States

     

      (d)

    Title of Class of Securities

    Common Stock

     

      (e)

    CUSIP Number

    31447P100


    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)    ☐    Insurance Company as defined in Section 3(a)(19) of the Act
    (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
    (e)    ☐    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)    ☐    Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4.

    Ownership***

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    As of December 31, 2020, the Master Fund owned 4,077,214 shares of Common Stock, which is 15.8% of the Issuer’s outstanding Common Stock. The percentage herein is calculated based upon the aggregate total of the 25,809,684 shares of Common Stock issued and outstanding assuming closing of the public offering, as reported by the Issuer in its quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission on November 16, 2020.

     

      (a)

    Amount Beneficially Owned***

    Southpoint Master Fund, LP - 4,077,214 shares

    Southpoint Capital Advisors LP - 4,077,214 shares

    Southpoint Capital Advisors LLC - 4,077,214 shares

    Southpoint GP, LP - 4,077,214 shares

    Southpoint GP, LLC - 4,077,214 shares

    John S. Clark II - 4,077,214 shares

     

      (b)

    Percent of Class

    Southpoint Master Fund, LP – 15.8%

    Southpoint Capital Advisors LP – 15.8%

    Southpoint Capital Advisors LLC – 15.8%

    Southpoint GP, LP – 15.8%

    Southpoint GP, LLC – 15.8%

    John S. Clark II – 15.8%


      (c)

    Number of shares as to which such person has:

     

      (i)

    sole power to vote or to direct the vote

    Southpoint Master Fund, LP - 0 shares

    Southpoint Capital Advisors LP - 0 shares

    Southpoint Capital Advisors LLC - 0 shares

    Southpoint GP, LP - 0 shares

    Southpoint GP, LLC - 0 shares

    John S. Clark II - 0 shares

     

      (ii)

    shared power to vote or to direct the vote

    Southpoint Master Fund, LP - 4,077,214 shares

    Southpoint Capital Advisors LP - 4,077,214 shares

    Southpoint Capital Advisors LLC - 4,077,214 shares

    Southpoint GP, LP - 4,077,214 shares

    Southpoint GP, LLC - 4,077,214 shares

    John S. Clark II - 4,077,214 shares

     

      (iii)

    sole power to dispose or to direct the disposition of

    Southpoint Master Fund, LP - 0 shares

    Southpoint Capital Advisors LP - 0 shares

    Southpoint Capital Advisors LLC - 0 shares

    Southpoint GP, LP - 0 shares

    Southpoint GP, LLC - 0 shares

    John S. Clark II - 0 shares

     

      (iv)

    shared power to dispose or to direct the disposition of

    Southpoint Master Fund, LP - 4,077,214 shares

    Southpoint Capital Advisors LP - 4,077,214 shares

    Southpoint Capital Advisors LLC - 4,077,214 shares

    Southpoint GP, LP - 4,077,214 shares

    Southpoint GP, LLC - 4,077,214 shares

    John S. Clark II - 4,077,214 shares

     

    ***

    Shares reported herein are held by Southpoint Master Fund, LP for which Southpoint Capital Advisors LP serves as the investment manager and Southpoint GP, LP serves as the general partner. Southpoint Capital Advisors LLC serves as the general partner of Southpoint Capital Advisors LP and Southpoint GP, LLC serves as the general partner of Southpoint GP, LP. John S. Clark II serves as managing member of both Southpoint Capital Advisors LLC and Southpoint GP, LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein.


    Item 5.

    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [    ].

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group

    Not applicable.

     

    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

    February 12, 2021

     

    SOUTHPOINT MASTER FUND, LP

    By:

     

    Southpoint GP, LP, its General Partner

    By:

     

    Southpoint GP, LLC, its General Partner

    By:

     

    /s/ John S. Clark II

    John S. Clark II, Managing Member

    SOUTHPOINT CAPITAL ADVISORS LP

    By:  

    Southpoint Capital Advisors LLC,

    its General Partner

    By:

     

    /s/ John S. Clark II

    John S. Clark II, Managing Member

    SOUTHPOINT CAPITAL ADVISORS LLC

    By:

     

    /s/ John S. Clark II

    John S. Clark II, Managing Member

    SOUTHPOINT GP, LP

    By:

     

    Southpoint GP, LLC, its General Partner

    By:

     

    /s/ John S. Clark II

    John S. Clark II, Managing Member

    SOUTHPOINT GP, LLC

    By:

     

    /s/ John S. Clark II

    John S. Clark II, Managing Member

    JOHN S. CLARK II

    By:

     

    /s/ John S. Clark II

    John S. Clark II, individually


    JOINT FILING AGREEMENT

    This Joint Filing Agreement, dated as of February 14, 2018, is by and among Southpoint Master Fund, LP, Southpoint Capital Advisors LP, Southpoint Capital Advisors LLC, Southpoint GP, LP, Southpoint GP, LLC and John S. Clark II (collectively, the “Filers”).

    Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/or 13G with respect to shares of Common Stock of Fennec Pharmaceuticals Inc. beneficially owned by them from time to time.

    Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13D and/or 13G (and any amendments thereto) on behalf of each of the Filers, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

    This Joint Filing Agreement may be terminated by any of the Filers upon written notice or such lesser period of notice as the Filers may mutually agree.

    Executed and delivered as of the date first above written.

     

    SOUTHPOINT MASTER FUND, LP

    By:

     

    Southpoint GP, LP, its General Partner

    By:

     

    Southpoint GP, LLC, its General Partner

    By:

     

    /s/ John S. Clark II

    John S. Clark II, Managing Member

    SOUTHPOINT CAPITAL ADVISORS LP

    By:

     

    Southpoint Capital Advisors LLC,

    its General Partner

    By:

     

    /s/ John S. Clark II

    John S. Clark II, Managing Member

    SOUTHPOINT CAPITAL ADVISORS LLC

    By:

     

    /s/ John S. Clark II

    John S. Clark II, Managing Member

    SOUTHPOINT GP, LP

    By:

     

    Southpoint GP, LLC, its General Partner

    By:

     

    /s/ John S. Clark II

    John S. Clark II, Managing Member

    SOUTHPOINT GP, LLC

    By:

     

    /s/ John S. Clark II

    John S. Clark II, Managing Member

    /s/ John S. Clark II

    John S. Clark II

    Get the next $FENC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FENC

    DatePrice TargetRatingAnalyst
    11/22/2022$9.00 → $12.00Neutral → Overweight
    Cantor Fitzgerald
    9/7/2022$11.00Overweight
    CapitalOne
    8/8/2022$14.00Buy
    Craig Hallum
    More analyst ratings

    $FENC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Fennec Pharmaceuticals upgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald upgraded Fennec Pharmaceuticals from Neutral to Overweight and set a new price target of $12.00 from $9.00 previously

      11/22/22 9:21:25 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CapitalOne initiated coverage on Fennec Pharmaceuticals with a new price target

      CapitalOne initiated coverage of Fennec Pharmaceuticals with a rating of Overweight and set a new price target of $11.00

      9/7/22 8:58:27 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Craig Hallum resumed coverage on Fennec Pharmaceuticals with a new price target

      Craig Hallum resumed coverage of Fennec Pharmaceuticals with a rating of Buy and set a new price target of $14.00

      8/8/22 8:53:55 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FENC
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Fennec Pharmaceuticals Inc.

      DEF 14A - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)

      4/25/25 4:25:31 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Fennec Pharmaceuticals Inc.

      10-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)

      3/26/25 4:34:57 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fennec Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)

      3/10/25 4:46:12 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FENC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Fennec Pharmaceuticals Inc.

      SC 13G/A - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)

      11/12/24 7:38:18 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Fennec Pharmaceuticals Inc.

      SC 13G - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)

      6/27/24 4:43:33 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Fennec Pharmaceuticals Inc.

      SC 13G - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)

      2/14/24 10:47:17 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FENC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      ~ Achieved First Quarter 2025 Total Net Revenues of $8.8 Million, Up 18% Year Over Year ~ ~ Positive Momentum from Company's Refined, Targeted Sales Strategy and Enhanced Patient Support Services ~ ~ PEDMARQSI Now Commercially Available in Germany and the United Kingdom ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., May 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today reported its financial results for the first quarter ended March 31, 2025 and provided a business update. "In the first quarter, we sharpened our strategic focus and achieved sustainable gro

      5/13/25 6:03:00 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

      RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date:Tuesday, May 13, 2025Time:8:30 a.m. ETWebcast Link:https://edge.media-server.com/mmc/p/nb5vbq6oParticipant Link:https://register-conf.media-server.com/register/BIbc2eaa3f157d4c6891b71246a83bdb02 To access the li

      5/8/25 4:17:00 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

      ~ Achieved Full-Year PEDMARK® Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK® Q4 2024 Net Product Sales of $7.9 Million ~ ~ Delivered Q4 2024 EBITDA Loss of $0.6 Million and Company Has $26.6 Million in Cash, Cash Equivalents and Short-Term Investments ~ ~ Completed Early Repayment of $13 Million of the Company's Convertible Debt Facility ~ ~ Continued Momentum in the Adolescent and Young Adult (AYA) Segment and Academic Setting Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~ PEDMARQSI® Now Commercially Available to Patients and Healthcare Providers in the United Kingdom and Germany ~ ~ Japan Clini

      3/10/25 6:03:00 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FENC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Raykov Rosty sold $63,100 worth of shares (10,000 units at $6.31), decreasing direct ownership by 16% to 53,587 units (SEC Form 4)

      4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

      5/5/25 6:23:15 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF FINANCIAL OFFICER Andrade Robert was granted 1,042 shares, increasing direct ownership by 0.79% to 133,633 units (SEC Form 4)

      4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

      5/1/25 6:03:46 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Raykov Rosty was granted 2,431 shares, increasing direct ownership by 4% to 63,587 units (SEC Form 4)

      4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

      5/1/25 6:03:04 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FENC
    Leadership Updates

    Live Leadership Updates

    See more
    • Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director

      ~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced Ototoxicity ~ RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced the appointment of Mr. Jeff Hackman as its Chief Executive Officer (CEO) and a member of the Board of Directors, effective on or about August 16, 2024. Jeff will guide Fennec's strategic direction for operational success in the expansion of PEDMARK® use in c

      8/5/24 6:26:00 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FENC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Andrade Robert bought 12,500 shares, increasing direct ownership by 14% to 104,271 units (SEC Form 4)

      4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

      4/3/24 5:00:11 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raykov Rosty bought 29,167 shares, increasing direct ownership by 10% to 316,638 units (SEC Form 4)

      4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

      4/3/24 4:55:10 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FENC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for PEDMARK issued to FENNEC PHARMACEUTICALS INC

      Submission status for FENNEC PHARMACEUTICALS INC's drug PEDMARK (ORIG-1) with active ingredient SODIUM THIOSULFATE has changed to 'Approval' on 09/20/2022. Application Category: NDA, Application Number: 212937, Application Classification: Type 5 - New Formulation or New Manufacturer

      9/20/22 3:54:04 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FENC
    Financials

    Live finance-specific insights

    See more
    • Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      ~ Achieved First Quarter 2025 Total Net Revenues of $8.8 Million, Up 18% Year Over Year ~ ~ Positive Momentum from Company's Refined, Targeted Sales Strategy and Enhanced Patient Support Services ~ ~ PEDMARQSI Now Commercially Available in Germany and the United Kingdom ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., May 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today reported its financial results for the first quarter ended March 31, 2025 and provided a business update. "In the first quarter, we sharpened our strategic focus and achieved sustainable gro

      5/13/25 6:03:00 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

      RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date:Tuesday, May 13, 2025Time:8:30 a.m. ETWebcast Link:https://edge.media-server.com/mmc/p/nb5vbq6oParticipant Link:https://register-conf.media-server.com/register/BIbc2eaa3f157d4c6891b71246a83bdb02 To access the li

      5/8/25 4:17:00 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

      ~ Achieved Full-Year PEDMARK® Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK® Q4 2024 Net Product Sales of $7.9 Million ~ ~ Delivered Q4 2024 EBITDA Loss of $0.6 Million and Company Has $26.6 Million in Cash, Cash Equivalents and Short-Term Investments ~ ~ Completed Early Repayment of $13 Million of the Company's Convertible Debt Facility ~ ~ Continued Momentum in the Adolescent and Young Adult (AYA) Segment and Academic Setting Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~ PEDMARQSI® Now Commercially Available to Patients and Healthcare Providers in the United Kingdom and Germany ~ ~ Japan Clini

      3/10/25 6:03:00 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care